20:05 , Aug 1, 2018 |  BC Innovations  |  Distillery Therapeutics

Neurology

INDICATION: Epilepsy Cell culture and rat studies suggest gene therapy delivering an engineered mutant chloride channel could help treat focal epilepsy. The mutant is a Caenorhabditis elegans glutamate-gated chloride channel engineered for increased sensitivity to...
16:04 , Jul 26, 2018 |  BC Innovations  |  Translation in Brief

Closing the loop

A University College London team has developed a chemogenetically activated gene therapy for refractory focal epilepsy that inhibits seizure-generating neurons in response to increased extracellular glutamate levels, a hallmark of seizures. The approach could provide...
17:56 , Apr 13, 2018 |  BC Week In Review  |  Financial News

Enterprise raises £29M series B

Respiratory company Enterprise Therapeutics Ltd. (Falmer, U.K.) raised £29 million ($40.9 million) on April 12 in a series B round led by Versant Ventures and Novartis Venture Fund. Also participating were new investor Forbion and...
08:17 , Apr 12, 2018 |  BC Extra  |  Financial News

Versant, Novartis Venture lead £29M round for Enterprise

Respiratory company Enterprise Therapeutics Ltd. (Falmer, U.K.) raised £29 million ($40.9 million) in a series B round led by Versant Ventures and Novartis Venture Fund. Also participating were new investor Forbion and existing investors Epidarex...
08:13 , Apr 12, 2018 |  BioCentury  |  Finance

Enterprise engages

Enterprise Therapeutics Ltd.’s belief that it can improve on existing mucus-clearing therapies led an investor syndicate to back the respiratory company in a £29 million ($40.9 million) series B round. Versant Ventures and Novartis Venture...
20:40 , Jan 5, 2018 |  BC Week In Review  |  Company News

Mallinckrodt acquiring Sucampo

Mallinckrodt plc (NYSE:MNK) said it will acquire Sucampo Pharmaceuticals Inc. (NASDAQ:SCMP) for $18 per share in a deal the companies say values Sucampo at $1.2 billion. The price is a 6% premium to Sucampo's close...
21:40 , Jan 3, 2018 |  BC Innovations  |  Product R&D

Expanding small molecule horizons

With a platform boasting more than a decade of preclinical rigor and $55.3 million in series A funding, Expansion Therapeutics Inc. is the latest company to step into the RNA-binding small molecule arena. The newco...
23:19 , Dec 26, 2017 |  BC Extra  |  Company News

Mallinckrodt acquiring Sucampo

Mallinckrodt plc (NYSE:MNK) said Tuesday it will acquire Sucampo Pharmaceuticals Inc. (NASDAQ:SCMP) for $18 per share in a deal the companies say values Sucampo at $1.2 billion. The price is a 6% premium to Sucampo's...
19:44 , Oct 3, 2017 |  BC Innovations  |  Distillery Therapeutics

Pulmonary

INDICATION: Cystic fibrosis (CF) Cell culture, patient sample and mouse studies suggest inhibiting the interaction of miR-9 with its negative regulator ANO1 could help treat mucus accumulation in CF. In bronchial epithelial cells from patients,...
22:11 , Apr 13, 2017 |  BC Innovations  |  Targets & Mechanisms

Cool and also collected

A Nature Medicine study published this week shows the immune-modulating peptide thymosin α1 provides unexpected improvements in the dysfunctional ion channel that causes cystic fibrosis, and could lead to a single agent therapy to compete...